BioAdvice is a GLP and GMP compliant preclinical Contract Research Organisation (CRO) located near Copenhagen, Denmark. The company was established in 1999 and is now driven by a young energetic team of skilled Study Directors, Veterinarians, Animal Technicians and Laboratory Technician.


We offer services within multiple areas of preclinical in-vivo drug testing, with emphasis on metabolism, inflammation and dermatology. We have specialized within pharmacokinetic (PK) and pharmacodynamic (PD) studies in multiple species; mice, rats, rabbits, minipigs, SPF pigs and beagle dogs. Dosing is performed at clinically relevant intervals by various administration routes as; intravenously, intramuscularly, subcutaneously and intradermally. Blood samples will be taken for analysis of test substances aiming at elucidating absorption, distribution, metabolism and excretion of the substances. Blood samples may also be taken for clinical chemistry and/or haematology.


We have a broad portfolio of performed studies, where our experiences and observations, help us continuously improve study designs and refine our technical procedures. E.g.


  • MRI (Magnetic Resonance Imaging) - bone and cartilage healing / repair
  • X-ray (C-arm) and ultrasound
  • Wound healing studies in pigs
  • Inflammatory tests
  • Toxicology studies, single and repeated dosing, local toxicity tests
  • Batch-release tests according to GMP incl. antigenic impurities in guinea pigs
  • Medical device testing
  • Surgical training


The modern facility and highly qualified monitoring skills at BioAdvice ensures high ethical standards with thorough individualised attention to any animal in your studies.

We aim at giving our customers high ethical standards, flexibility and high quality at any time.

BIOADVICE A/S, LYSHØJVEJ 21, 3650 ØLSTYKKE, DENMARK  +4538252015   BIOADVICE@BIOADVICE.DK

BIOADVICE A/S, 21 LYSHØJVEJ, ØLSTYKKE, 3650, DENMARK   +4538252015

BIOADVICE@BIOADVICE.DK

Go to article: Home | The Scottish Uprising Go to article: In this issueGo to article: NSFGo to article: ContentsGo to article: Daiichi JitsugyoGo to article: NewsGo to article: Hapa Company InsightGo to article: BioadviceGo to article: The pharma industry briefingGo to article: Komtur Pharmaceuticals Company InsightGo to article: Komtur PharmaceuticalsGo to article: Where is the UK’s supply of Migraleve?Go to article: AtoZ-CRO GmbH Company InsightGo to article: AtoZ-CRO GmbHGo to article: Drugs from corn? Harvesting Mirexus’ phytoglycogen nano-particleGo to article: Phoenix Group Company InsightGo to article: Phoenix Group Go to article: Castleman disease: does machine learning hold the key to better treatment?Go to article: Capsugel Company InsightGo to article: CalleryGo to article: A health check for Scotland’s pharmaceutical industry Go to article: ImmuMap Company Insight Go to article: ImmuMapGo to article: Moderna’s gamble: what’s behind biotech’s biggest-ever IPO?Go to article: Centaur Clinical | Company InsightGo to article: Centaur ClinicalGo to article: DelSiTech: leveraging silica’s properties to improve drug deliveryGo to article: Alpex Pharma Go to article: AlbypharmaGo to article: ‘Gene genie’: can CRISPR/Cas9 deliver on its promise to transform genome therapy?Go to article: ZenatekGo to article: EventsGo to article: SanofiGo to article: Event: CPhl JapanGo to article: PfanstiehlGo to article: Next issue